Seven Bridges Selected by Pfizer to Support Data Management Solution for Single-Cell RNA Sequencing Data

 
 

- Seven Bridges, the industry-leading bioinformatics ecosystem provider, is supporting Pfizer Inc. (NYSE: PFE) in the development of a data management and collaboration solution for the biopharmaceutical company's single-cell ribonucleic acid (RNA) sequencing (scRNASeq) data. The Seven Bridges Platform is a cloud-based environment for conducting bioinformatic analyses in which research teams can store, analyze and interpret their data. The partnership will introduce avenues to expand Pfizer's cloud platforms and capabilities, a key component of Pfizer's integrated digital cloud and advanced analytics strategy.

 
 

  (PRNewsfoto/Seven Bridges Genomics Inc.) 

 
 

Seven Bridges will support Pfizer by centralizing and managing terabytes of raw and processed scRNASeq data. scRNASeq data provides detailed analysis of gene expression in individual cells.

 

"Interpreting large-scale, complex transcriptomics data is critically important for understanding the molecular and cellular basis of disease," said Enoch Huang , Vice President, Medicinal Sciences, Pfizer. "We are confident that by working with the unique multi-cloud technology developed by Seven Bridges and by benefiting from the depth and breadth of their expertise in bioinformatics and cloud computing, their solution will assist us in maximizing the value of the data we generate."

 

Sequencing RNA provides fundamental insights into the regulation of genomes. scRNASeq―that is, when researchers focus on just an individual cell and take a 'snapshot' of the gene expression dynamics―yields potentially useful information, but the scRNASeq data carry a very large data footprint.

 

The Seven Bridges Platform provides a cost-effective, secure, end-to-end, scalable, durable and reliable data storage-and-management solution that increases accessibility and analysis of scRNASeq data across entire organizations and the public domain, ensuring optimal utility of sequencing data, reducing experiment repetition, and saving time and money.

 

"Seven Bridges believes that genomics—and single-cell RNA sequencing in particular—will continue to play an increasingly vital role in the discovery of novel drugs and vaccines," said Bill Moss , CEO, Seven Bridges. "We are thrilled that Pfizer has chosen our platform to help the company address these unique data management needs. And we look forward to supporting the development of a scRNASeq data storage solution that meets Pfizer's research and development requirements."

 

  About Seven Bridges
Seven Bridges enables researchers to extract meaningful insights from genomic and phenotypic data in order to advance precision medicine. The Seven Bridges Ecosystem consists of a compliant analytic platform, intelligently curated content, transformative algorithms, unprecedented access to federated data sets, and expert on-demand professional services. This holistic approach to bioinformatics is enabling researchers — at the world's leading academic, biotechnology, clinical diagnostic, government, medical centers, and pharmaceutical entities — to increase R&D efficiency, enhance the hypothesis resolution process, isolate critical biomarkers, and even turn a failing clinical trial around while also reducing computational workflow times and data storage costs. To learn more, visit   sevenbridges.com   or follow us on   LinkedIn   and   Twitter   .

 

  Media Contacts  

 

  Eric Schubert  

 

Seismic for Seven Bridges

 

+1 415 692 6799

 

  sevenbridges@teamseismic.com  

 
 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/seven-bridges-selected-by-pfizer-to-support-data-management-solution-for-single-cell-rna-sequencing-data-301234059.html  

 

SOURCE Seven Bridges

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Invion Limited

Invion Limited

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial

Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients
with acute myocarditis, with topline data expected in Q2 2025

Keep reading...Show less

Latest Press Releases

Related News

×